VANCOUVER, BC, Jan. 25, 2021/PRNewswire/ – Notch Therapeutics Inc., a biotechnology organization creating inexhaustible immature microorganism stem cell treatments for malignancy and other resistant problems, reported today the arrangement of Chris Bond, Ph.D. as Senior Vice President, Preclinical and Translational Sciences. Dr. Bond joins Notch from Kite, where he most as of late filled in as Vice President of Cellular Engineering.
“We are eager to invite Chris, a profoundly respected medication designer and group manufacturer who brings to Notch incredible profundity of involvement and skill being developed of cell treatments, quality altering, and cell designing spreading over disclosure through IND,” said David Main, President and Chief Executive Officer of Notch. “Adding Chris to our administration group will reinforce our preclinical pipeline and translational examination abilities to quicken advancement of the organization’s cell treatment up-and-comers from revelation into clinical application.”
Chris Bond, Ph.D., Senior Vice President, Preclinical and Translational Sciences
Chris Bond gets Notch together with over 18 years of involvement working with biotechnology and drug organizations including Genentech, OncoMed, Juno Therapeutics, Celgene, and Kite. Dr. Bond has broad involvement with the disclosure and improvement of assenting cell treatments, monoclonal antibodies, and cell designing and genome altering. At Juno and at Kite, he drove the disclosure and preclinical improvement programs for CAR T and TCR cell treatments focusing on strong and hematological tumors. At Kite, Dr. Bond drove the improvement of allogeneic cell treatment stages utilizing T cells from both benefactor inferred sources and incited pluripotent immature microorganisms. As a feature of his work with Juno and Kite, Dr. Bond drove R&D coordinated efforts with genome altering organizations including Editas Medicine and Sangamo Therapeutics. The use of stem cells for pain management is rapidly gaining interest. Preceding his work in receptive cell treatment, Dr. Bond drove monoclonal and bi-explicit immunizer revelation and designing projects focusing on disease immature microorganism antigens at OncoMed Pharmaceuticals. He is a designer on various licenses and has distributed papers in the fields of protein construction and designing, immunology, and oncology. Dr. Bond got a Ph.D. in Biochemistry from the University of Washington.
About Notch Therapeutics (www.notchtx.com)
Score is an innovator in the improvement of cell therapeutics starting from pluripotent undifferentiated organisms that are explicitly designed to address the basic science of complex sickness frameworks. The organization has opened the capacity for enormous amount creation of T cells and different cells from any wellspring of foundational microorganisms to acquire best class cell treatment items to a great many patients. The center of the Notch stage is the Engineered Thymic Niche (ETN), which empowers accuracy control of cell destiny during the separation and extension of immature microorganisms, with the possibility to create immunotherapies with diminished inconstancy, expanded power, and designed enhancements. The ETN stage is the principal innovation that can dependably create T cells from iPSC-inferred forebear cells utilizing completely characterized, non-xenogenic reagents, which can possibly significantly improve the administrative, clinical, and business ascribes for these inventive meds. The innovation was developed in the labs of Juan-Carlos Zúñiga-Pflücker, Ph.D. at Sunnybrook Research Institute and Peter Zandstra, Ph.D., FRSC at the University of Toronto. Score was established by these two organizations, related to MaRS Innovation (presently Toronto Innovation Acceleration Partners) and the Center for Commercialization of Regenerative Medicine (CCRM) in Toronto.